Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2022-07-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押展期的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the extension of a pledge on shares held by a controlling shareholder. It details the number of shares pledged, the pledge period, and related shareholder information. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge extension, which fits best under the category of Capital/Financing Update (CAP) as it relates to financing activities involving share pledges by major shareholders.
2022-07-15 Chinese
关于环泊酚注射液新适应症上市申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company 海思科医药集团股份有限公司 regarding the approval of a new indication for a pharmaceutical product (环泊酚注射液) by the National Medical Products Administration (国家药品监督管理局). It details the drug's registration certificate, new approved indication, and related drug information. The document is short (1107 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a regulatory filing in the sense of compliance or certification documents but rather a regulatory announcement about product approval. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like financial reports or management information.
2022-07-14 Chinese
2022年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2022, issued by the company. It provides estimated financial results and explanations for changes compared to the previous year. It explicitly states that the financial data have not been audited and that detailed financial data will be disclosed in the company's 2022 half-year report. The document is short (805 characters) and serves as a preliminary earnings forecast rather than a full interim or quarterly report containing actual financial statements. Therefore, it is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. H1 2022
2022-07-14 Chinese
关于公司产品拟中选第七批全国药品集中采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company regarding its products being proposed for selection in the seventh batch of a national centralized drug procurement. It details the products, their specifications, pricing, procurement period, and supply regions. The document also discusses the potential impact on the company and includes a risk warning. There are no financial statements, no detailed financial performance data, no management discussion of results, no voting results, no regulatory certifications, or other report types. The document is an announcement of a business event related to product procurement and market impact. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial data. It is a regulatory announcement about a business development. Given the content and length (1496 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-07-13 Chinese
关于复方氨基酸（18AA）葡萄糖（15%）电解质注射液独家通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the exclusive approval of a pharmaceutical product passing a generic drug consistency evaluation by the National Medical Products Administration of China. It includes details about the drug, regulatory approval, and risk warnings. The document is short (1287 characters) and does not contain financial data, earnings, or management discussion. It is an official announcement of a regulatory approval event, not a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-07-07 Chinese
关于《专利实施许可协议及相关协议之解除协议》交易进展的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company Haise Medical Group Co., Ltd. regarding the progress of a transaction related to the termination of a patent license agreement and related agreements. It details payment receipts and revisions to the agreement, with references to previous announcements. The document is short (755 characters) and focuses on transaction progress and payment updates rather than full financial statements or detailed financial analysis. It does not contain comprehensive financial data or results, nor is it a report or presentation. This fits the category of a Capital/Financing Update (CAP), as it relates to transaction progress and payment updates in a financing or capital context.
2022-06-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.